Drug

Iloprost

Approved · FDA / EMA

Emerging researchLate-stage development

Also known as Aurlumyn, Ventavis, PENTANOIC ACID, 5-((3AS,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-2(1H)-PENTALENYLIDENE)-, (5E)-.

RxNorm40138 ChEMBLCHEMBL494UNIIJED5K35YGL

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: ILOPROST (ANDA214997)

Regulatory2026-07-10FDA

Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease: Multicenter, Randomized, Double-blind, Placebo-controlled Study

Clinical trial2026-03-27Results expected Q1 2030 · ClinicalTrials.gov

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng/kg/Min) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial

Clinical trial2025-08-22Results expected Q3 2027 · ClinicalTrials.gov

A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

" ILOPROST for Treatment of Septic Shock With Persistent Microperfusion Defects ", a Double-blind, Randomized Controlled Trial:The I-MICRO Trial

Clinical trial2024-01-18Completed · ClinicalTrials.gov

A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers

Clinical trial2023-08-30Completed · ClinicalTrials.gov

Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery: a Randomized, Blinded Clinical Trial

Clinical trial2022-12-01Primary completion · ClinicalTrials.gov

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/Kilo(kg)/Minute(Min)) in Patients With Septic Shock Induced Endotheliopathy - a Multicentre Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial"

Clinical trial2022-06-28Completed · ClinicalTrials.gov

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/Kilogram(kg)/Minute(Min)) in Trauma Patients With Haemorrhagic Shock Induced Endotheliopathy.

Clinical trial2021-11-14Completed · ClinicalTrials.gov

Therapeutic Iloprost for the Treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial)

Clinical trial2021-08-14Completed · ClinicalTrials.gov

Oral iloprost improves endobronchial dysplasia in former smokers.

Research2011-06-01Cancer prevention research (Philadelphia, Pa.)

Approval: Ventavis (EMA)

Regulatory2003-09-15EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Iloprost

Aliases & brands

AurlumynVentavisPENTANOIC ACID, 5-((3AS,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-2(1H)-PENTALENYLIDENE)-, (5E)-

RxNorm CUI

40138

ChEMBL ID

CHEMBL494

UNII

JED5K35YGL

Regulatory jurisdictions

emafda

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2003-09-15

Latest approval

2026-07-10

Authorities

FDA · EMA

Total events

fdaU.S. Food and Drug Administration· 1 event

2026-07-10Approval

Approval: ILOPROST (ANDA214997)

Evidence ↗

emaEuropean Medicines Agency· 1 event

2003-09-15Approval

Approval: Ventavis (EMA)

Indication: Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.